Evidence map›Paper›PMID 35191185›Full record

SynthesisJournal of diabetes investigation2022

Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta-analysis.

Kaixin Duan, Xiaolu Yan, Zhe Gao, Yilin Hou, Xiuqin Lv, Guangyao Song

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Observational
  7. Review
  8. Clinical and Radiological Fusion: A New Frontier in Predicting Post-Transplant Diabetes Mellitus.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kaixin DuanGraduate School of Hebei North University, Zhangjiakou, China.
Xiaolu YanDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.
Zhe GaoDepartment of Endocrinology, Hebei General Hospital, Shijiazhuang, China.ORCID https://orcid.org/0000-0001-5087-349X
Yilin HouDepartment of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
Xiuqin LvDepartment of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
Guangyao SongDepartment of Endocrinology, Hebei General Hospital, Shijiazhuang, China.ORCID https://orcid.org/0000-0002-9901-6074
Hebei General Hospital · CNHebei North University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS/

introductionGlucagon-like peptide-1 receptor agonists (GLP-1Ras) are widely used to treat type 2 diabetes. They not only reduce glucose, but also have a positive effect on weight loss. However, few studies have reported the effect of GLP-1Ras on fat distribution. MATERIALS AND

methodsPubMed, Cochrane, Embase and ClinicalTrials.gov were searched for randomized controlled trials on GLP-1Ras and type 2 diabetes, published from inception to June 2021. Our main outcomes were the reductions of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). Other anthropometric outcomes were also assessed. We used the Cochrane Collaboration tools to assess the risk of bias in the included studies. The quality of the evidence was assessed using the Grades of Recommendation, Assessment, Development and Evaluation profiler version 3.6. Review Manager 5.4.1 and Stata 16.0 were used for data analysis.

resultsA total of 10 studies involving 541 patients were included. Compared with the control groups, the GLP-1Ras groups showed reductions in VAT (standard mean difference -0.54, 95% confidence interval [CI] -0.92, -0.17, I

conclusionThis study highlights that GLP-1Ras, especially liraglutide and exenatide, might play an active role in fat distribution in patients with type 2 diabetes. After treatment with GLP-1Ras, both VAT and SAT decreased, and the decrease of VAT was numerically greater than that of SAT.

Indexed as

Diabetes Mellitus, Type 2ExenatideGlucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsLiraglutideExenatideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLiraglutideFat distributionGlucagon-like peptide-1Type 2 diabetes

Identifiers

PMID35191185
PMCPMC9248433
OpenAlexW4212818070

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.